Expression of programmed death-ligand 1 and hypoxia-inducible factor-1a proteins in endometrial carcinoma

被引:22
作者
Tawadros, Ashraf Ishak Fawzy [1 ]
Khalafalla, Mohamed Mohamed Mohamed [2 ]
机构
[1] Menia Univ, Dept Pathol, Fac Med, Al Minya, Egypt
[2] Menoufia Univ, Dept Obstet & Gynecol, Fac Med, Al Menoufia, Egypt
关键词
Clinicopathologic variables; endometrial carcinoma; hypoxia-inducible factor-1a; immunohistochemistry; programmed death-ligand 1; SQUAMOUS-CELL CARCINOMA; POOR-PROGNOSIS; PD-L1; EXPRESSION; GENE-EXPRESSION; CANCER; TUMOR; ADENOCARCINOMA; HIF-1-ALPHA; HIF1-ALPHA; BLOCKADE;
D O I
10.4103/0973-1482.202891
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Programmed death-ligand 1 (PD-L1) and hypoxia-inducible factor-1a (HIF-1a) proteins mediate major alterations of tumor microenvironment including generation of immunosuppressive microenvironment and tumor hypoxia, respectively. These alterations play a crucial role in carcinogenesis and tumor progression. Aims: The present study was designed to investigate the correlation between the expression of PD-L1 and HIF-1a proteins and the clinicopathologic variables in endometrial carcinoma. Materials and Methods: Tumor tissue sections from 95 endometrial carcinomas were evaluated for PD-L1 and HIF-1a immunohistochemical protein expression. Statistical Analysis Used: The statistical analyses were performed using Chi-square and Fisher's exact tests when appropriate. Two-sided P < 0.05 was considered statistically significant. Results: PD-L1 and HIF-1a expression were detected in 48.4% and 68.4% of endometrial carcinomas, respectively. PD-L1 expression was significantly associated with lymph node metastasis (P = 0.027). HIF-1a expression was significantly associated with tumor grade, depth of myometrial invasion, and lymph node metastasis (P = 0.014, 0.012, and 0.046, respectively). A significant positive correlation was detected between PD-L1 and HIF-1a immunoexpression (P = 0.015). Conclusions: PD-L1 and HIF-1a proteins are promising potential prognostic biomarkers in endometrial carcinomas since their overexpression is associated with clinicopathologic variables of advanced disease. A potential role of HIF-1a in upregulation of PD-L1 expression is suggested based on the finding of positive correlation between PD-L1 and HIF-1a expression in endometrial carcinoma. These findings point to a potential role of biomarkers inhibitors in controlling endometrial cancer progression.
引用
收藏
页码:S1063 / S1069
页数:7
相关论文
共 39 条
  • [21] Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
    Meng, Xiangjiao
    Huang, Zhaoqin
    Teng, Feifei
    Xing, Ligang
    Yu, Jinming
    [J]. CANCER TREATMENT REVIEWS, 2015, 41 (10) : 868 - 876
  • [22] Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    Muenst, S.
    Schaerli, A. R.
    Gao, F.
    Daester, S.
    Trella, E.
    Droeser, R. A.
    Muraro, M. G.
    Zajac, P.
    Zanetti, R.
    Gillanders, W. E.
    Weber, W. P.
    Soysal, S. D.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 146 (01) : 15 - 24
  • [23] Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer
    Nalwoga, Hawa
    Ahmed, Lavina
    Arnes, Jarle B.
    Wabinga, Henry
    Akslen, Lars A.
    [J]. PLOS ONE, 2016, 11 (01):
  • [24] PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
    Noman, Muhammad Zaeem
    Desantis, Giacomo
    Janji, Bassam
    Hasmim, Meriem
    Karray, Saoussen
    Dessen, Philippe
    Bronte, Vincenzo
    Chouaib, Salem
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (05) : 781 - 790
  • [25] Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Ohaegbulam, Kim C.
    Assal, Amer
    Lazar-Molnar, Eszter
    Yao, Yu
    Zang, Xingxing
    [J]. TRENDS IN MOLECULAR MEDICINE, 2015, 21 (01) : 24 - 33
  • [26] Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells
    Oliveira-Costa, Joao Paulo
    de Carvalho, Alex Fiorini
    da Silveira, Giorgia Gobbi
    Amaya, Peter
    Wu, Yongqi
    Park, Kyoung-Joo Jenny
    Gigliola, Mabel Pinilla
    Lustberg, Maryam
    Cavicchioli Buim, Marcilei Eliza
    Ferreira, Elisa Napolitano
    Kowalski, Luiz Paulo
    Chalmers, Jeffrey J.
    Soares, Fernando Augusto
    Carraro, Dirce Maria
    Ribeiro-Silva, Alfredo
    [J]. ONCOTARGET, 2015, 6 (25) : 20902 - 20920
  • [27] Increased expression of hypoxia-inducible factor 1α in type I and type II endometrial carcinomas
    Pansare, Vaishali
    Munkarah, Adnan R.
    Schimp, Veronica
    Arabi, M. Haitham
    Saed, Ghassan M.
    Morris, Robert T.
    Ali-Fehmi, Rouba
    [J]. MODERN PATHOLOGY, 2007, 20 (01) : 35 - 43
  • [28] Prat J., 2014, World Health Organization Classification of Tumours of Female Reproductive Organs, P154
  • [29] The Role of Hypoxia-Inducible Factor-1α, Glucose Transporter-1, (GLUT-1) and Carbon Anhydrase IX in Endometrial Cancer Patients
    Sadlecki, Pawel
    Bodnar, Magdalena
    Grabiec, Marek
    Marszalek, Andrzej
    Walentowicz, Pawel
    Sokup, Alina
    Zegarska, Jolanta
    Walentowicz-Sadlecka, Malgorzata
    [J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [30] Programmed death-1/programmed death-1 ligand axis as a therapeutic target in oncology: current insights
    Schalper, Kurt A.
    Venur, Vyshak Alva
    Velcheti, Vamsidhar
    [J]. JOURNAL OF RECEPTOR LIGAND AND CHANNEL RESEARCH, 2015, 8 : 1 - 7